Lead · Compliance
South Carolina Restricts Research-Grade Peptides and Compounding Powders
South Carolina Medical Board Restricts Use of Research-Grade Peptides and Raw Compounding Powders
The South Carolina Board of Medical Examiners issued a formal notice on August 18, 2026, warning against and strictly restricting the use of research-grade, non-FDA-approved peptides and raw compounding powders in patient care. This decision directly impacts practices offering medical weight loss and wellness therapies, particularly those utilizing semaglutide and semaglutide salt forms. Under the new directive, physicians are explicitly prohibited from compounding, administering, dispensing, prescribing, recommending, or delegating the use of these "research-grade" substances to Advanced Practice Registered Nurses (APRNs) or Physician Assistants (PAs).
